# Entacapone

## Comtan 200mg

##### 

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | OCOMT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Indications        | Pregnancy & lactation. Liver impairment. Pheochromocytoma. Concomitant use w/ non-selective MAO-A & MAO-B inhibitors. Concomitant use w/ a selective MAO-A plus a selective MAO-B inhibitor. History of neuroleptic malignant syndrome (NMS) &/or non-traumatic rhabdomyolysis.                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Entacapone is used in combination with either levodopa/carbidopa or levodopa/benserazide. Other antiparkinsonian drugs may be used simultaneously. Give 200 mg orally with each dose of levodopa/dopa-decarboxylase inhibitor， up to a maximum of 10 times daily (maximum daily dose: 2000 mg); reductions in daily levodopa dose or extension of levodopa dosing intervals may be necessary to optimize patient's response. If entacapone treatment is discontinued， it is necessary to adjust the dosage of other antiparkinsonian treatments， especially levodopa， to achieve a sufficient level of control of the parkinsonian symptoms. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Management of Parkinson's disease as an adjunct to levodopa therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Dyskinesia; GI symptoms; urine discoloration; fatigue， insomnia， paranoia， confusion， hallucinations; dizziness， postural hypotension， vertigo， headache; leg cramps， hyperkinesia， tremor， increased sweating; slight decrease in Hb， erythrocyte count， & hematocrit. Rarely， increases in liver enzymes.                                                                                                                                                                                                                                                                                                                         |
| Pregnancy          | No (limited) human data – animal data suggest moderate risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

